Avastin May Help Fight Tough-to-Treat Ovarian Tumors

<p>SATURDAY, Jun 2 (HealthDay News) French researchers report
that a targeted therapy already enlisted in a quarrel opposite colorectal
cancer, lung cancer and kidney cancer might also have a purpose to play in
recalcitrant ovarian cancer.
According to investigate being presented Saturday during a American Society
of Clinical Oncology (ASCO) annual assembly in Chicago, Avastin
(bevacizumab) doubled a time to cancer regularity in women who were not
responding to normal chemotherapy.
This is a initial time that there has been a poignant allege in
these difficult-to-treat patients, pronounced investigate author Dr. Eric
Pujade-Lauraine, conduct of medical oncology during Hopitaux Universitaires
Paris-Centre site Hotel-Dieu, in France. These information open a new epoch for
biologics when chemotherapy is not doing a pursuit in memorable ovarian
cancer.
According to Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic
surgeon with Lenox Hill Hospital in New York City, some physi...